Tools and techniques – Page 11
-
ArticleNavigating the AI revolution: a roadmap for pharma's future
AI-driven drug development, powered by advanced models and expanding data access, is becoming a reality. Learn why navigating regulatory hurdles and mastering biology’s inherent complexities are crucial to fully unlocking its potential.
-
ArticleNew insights into surfactant spread for lung drug delivery
A recent study led by Dr Richard McNair highlights the role of the Marangoni effect in surfactant spreading, offering potential improvements in drug development and delivery for lung diseases.
-
ArticleRefining and targeting exatecan with ADC technology
DTR speaks with Dr Patrick van Berkel at ADC Therapeutics to discuss how the company is transforming exatecan delivery to achieve better health outcomes.
-
ArticleShattering the glass ceiling: empowering women and girls in STEM
On International Women’s Day, Assistant Professor Vasiliki E Kalodimou calls for greater commitment to closing the gender gap in STEM. Highlighting the need for gender-neutral education, stronger female representation and actionable strategies to break the glass ceiling, Kalodimou wants women’s participation in innovation to become the norm, not the exception.
-
ArticleEmpowering women in STEM: Navigating CMC regulatory affairs
Discover how a leader in CMC regulatory affairs is transforming drug development and inspiring the next generation of scientists.
-
ArticleHope for ALS and inflammatory diseases: Cellenkos' CRANE technology breakthrough
Cellenkos' CRANE technology, led by Dr Simrit Parmar, harnesses regulatory T cells to precisely target and treat inflammatory diseases. This innovative approach offers hope for conditions like aplastic anaemia, myelofibrosis, and ALS.
-
ArticleThe future of cell therapy: scaling production for global reach
Scaling up cell therapy is no easy feat. PluriCDMO's Andy Lewin reveals the critical factors for success and how they are helping companies bring life-saving therapies to market.
-
ArticleObesity care gets personalised: tailoring therapies with Phenomix
Find out how Phenomix Sciences is transforming obesity treatment by identifying patient subtypes for more targeted and effective therapies.
-
Article
Building better brain models for Parkinson’s disease and beyond
Professor Jens Christian Schwamborn is advancing personalised medicine for Parkinson’s disease using patient-specific brain organoids, offering new hope for more effective and targeted treatments.
-
ArticleNew therapy shows promise in strengthening CAR-T responses
CAR-T therapy has shown effectiveness in cancer treatment, but relapse often occurs due to limited cell persistence. New strategies aim to improve CAR T-cell durability for longer lasting remission.
-
ArticleLarge language models: now more affordable and reliable than ever
In this article, Dr Raminderpal Singh explores the transformative impact of the Deepseek R1 open-source large language model on drug discovery. Its potential offers exciting opportunities for both scientists and software developers, marking a significant advancement for the life sciences community.
-
ArticleEmpowering women in STEM: championing change in genetics
An advocate for genetic medicines and the enormous potential they hold, Leah Sabin at Regeneron Genetic Medicines reveals how passion and curiosity can forge the path to a rewarding career in STEM.
-
ArticleExperts explore the future of iPSC-based cell therapies
Discover the transformative potential of iPSC-based therapies in regenerative medicine, alongside their challenges including scalability, safety and targeted delivery.
-
ArticleLandmark study aims to detect Parkinson’s before symptoms
Grifols' Chronos-PD initiative leverages its extensive plasma repository to identify early biomarkers of Parkinson's disease, advancing early detection and contributing to the development of innovative therapies.
-
ArticleScientific workflow for hypothesis testing in drug discovery: part 3 of 3
Drug discovery scientists develop and test complex hypotheses using data and expertise, and build workflows to support this. In this third and final article, Dr Raminderpal Singh and Nina Truter summarise the tools used in the scientific workflow – and include key considerations.
-
ArticleUsing clinical genomics and AI in drug development to elevate success
How are clinical genomics and AI transforming drug development? Industry experts reveal how these technologies improve target identification, patient stratification, and trial design to drive higher success rates.
-
ArticleNew cell therapy model accelerates cancer treatment development
CTMC, a joint venture between Resilience + MD Anderson Cancer Center, is transforming cancer treatment with faster, more efficient cell therapy development - learn how they’re doing it.
-
ArticleNew study links type 2 diabetes to accelerated cognitive decline
Study reveals how type 2 diabetes accelerates cognitive decline by damaging white matter in the brain. Sam Hashemi at Prenuvo explains how advanced AI and whole-body MRI technology are opening new possibilities for early intervention.
-
ArticlePromising Alzheimer’s drug earns FDA fast-track designation
Posdinemab, being investigated by Johnson & Johnson, has received FDA fast-track status. Hear from Dr Fiona Elwood as she explains how Johnson & Johnson’s precision medicine approach could transform Alzheimer’s treatment.
-
ArticleCilta-cel: A new era in multiple myeloma treatment
New cell therapy, Cilta-cel, shows promise in the treatment of multiple myeloma, providing a personalised approach with the potential for long-term remission.
